HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Johnson & Johnson

www.jnj.com

Latest From Johnson & Johnson

Could A Type 1 Diabetes Immunotherapy Be In Reach?

Promising data from the likes of Provention Bio and Diamyd Medical suggest that treatment for the autoimmune disorder type 1 diabetes could soon move beyond insulin.

Clinical Trials Metabolic Disorders

Global Health Systems Are Learning To Embrace AI As A Force For Good

The term artificial intelligence was coined at the Dartmouth Summer Research Project in 1956, but it is only in very recent years that it has been consistently at the top of the agenda in discussions on the future direction of health care. As a tool to improve both the quality and speed of care, AI is now increasingly seen as a realistic solution to the demand overload on clinicians. At the same time, techno-fears are abating. This confluence will transform health care radically in the next two decades.

Outlook 2020 Artificial Intelligence

Hello NMPA: China Approval For Astellas's Xtandi, Keytruda Set For Fourth Indication

Astellas’s Xtandi gets its latest approval in China, where Merck’s Keytruda is set for another win.

China Regulation

US Senate Finance Drug Pricing Bill Would Have ‘Negligible’ Impact, Analyst Predicts

Now that US drug pricing reform seems inevitable, the Senate bill offers the most positive outcome for industry, Bernstein analyst Ronny Gal suggests. 

Pricing Debate Legislation
See All

Company Information

UsernamePublicRestriction

Register